AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Nov 9 (Reuters) - SANOFI SA:
* MHRA GRANTS APPROVAL OF BEYFORTUS (NIRSEVIMAB) FOR PREVENTION OF RSV DISEASE IN INFANTS
* NIRSEVIMAB IS FIRST BROADLY PROTECTIVE OPTION AGAINST RSV DISEASE FOR NEWBORNS AND INFANTS
* RESULTS FROM CLINICAL DEVELOPMENT PROGRAMME REINFORCE NIRSEVIMAB'S CONSISTENCY IN REDUCING RSV INFECTIONS REQUIRING MEDICAL CARE, INCLUDING HOSPITALISATIONS
* NIRSEVIMAB IS BEING DEVELOPED JOINTLY BY SANOFI AND ASTRAZENECA Source text for Eikon: Further company coverage: (Gdansk Newsroom)